| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000040506 |
| Receipt No. | R000046239 |
| Scientific Title | Cancer gene panel of plasma DNA in patients with solid tumor |
| Date of disclosure of the study information | 2020/05/26 |
| Last modified on | 2020/05/25 (Ver. 1) |
| Basic information | ||
| Public title | Cancer gene panel of plasma DNA in patients with solid tumor | |
| Acronym | Cancer gene panel of plasma DNA in patients with solid tumor | |
| Scientific Title | Cancer gene panel of plasma DNA in patients with solid tumor | |
| Scientific Title:Acronym | Cancer gene panel of plasma DNA in patients with solid tumor | |
| Region |
|
|
| Condition | ||
| Condition | Solid tumor | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | To evaluate the gene analysis of plasma DNA by NGS in patients with metastatic solid tumor |
| Basic objectives2 | Bio-equivalence |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Detection rate of somatic gene alterations in plasma DNA |
| Key secondary outcomes | Detection rate of somatic gene alterations in plasma DNA by cancer type.
Detection rate of somatic gene alterations in plasma DNA by gene. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Patinets with metastatic solic tumor
2) Age >= 20 years old 3) Patients with tumor harboring gene alteration 4) Written informed consent |
|||
| Key exclusion criteria | None | |||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Shizuoka Cancer Center Research Institute | ||||||
| Division name | Cancer Diagnostics Research Division | ||||||
| Zip code | 411-8777 | ||||||
| Address | 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun | ||||||
| TEL | 0559895222 | ||||||
| k.urakami@scchr.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Shizuoka Cancer Center | ||||||
| Division name | Division of Genetic Medicine Promotion | ||||||
| Zip code | 411-8777 | ||||||
| Address | 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun | ||||||
| TEL | 0559895222 | ||||||
| Homepage URL | |||||||
| h.kenmotsu@scchr.jp | |||||||
| Sponsor | |
| Institute | Shizuoka Cancer Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Shizuoka Cancer Center |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Shizuoka Cancer Center IRB |
| Address | 1007 Shimonagakubo, Nagaizumi-cho |
| Tel | 0559895222 |
| rinsho_office@scchr.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | 20 mL blood sample will be obtained from patiets emrolled into this study. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046239 |